We have a unique combination of intellectual assets, commercial capabilities, global reach and strategic focus required to successfully develop and market biosimilar drugs. Founded in 2010 as a pure-play biosimilar platform company, Coherus is devoted to expanding patient access to these life-changing therapeutics in major regulated markets around the world. Indeed, we believe Coherus is the only standalone biosimilars company with the insights and assets needed to succeed in this mission.